AAAAAA
Results:
1-8
|
Results: 8
Authors:
Bar, JK
Harlozinska, A
Popiela, A
Noga, L
Citation: Jk. Bar et al., Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: Response to cisplatin-based chemotherapy, TUMOR BIOL, 22(2), 2001, pp. 83-91
Authors:
Bar, JK
Harlozinska, A
Sedlaczek, P
Kasiak, J
Markowska, J
Citation: Jk. Bar et al., Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infectionin cervical carcinomas and cervical dysplasias, ANTICANC R, 21(2A), 2001, pp. 1001-1006
Authors:
Porebska, I
Harlozinska, A
Bojarowski, T
Citation: I. Porebska et al., Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2. ERB B3) in colorectal adenocarcinomas and adenomas, TUMOR BIOL, 21(2), 2000, pp. 105-115
Authors:
Van Dalen, A
Favier, J
Baumgartner, L
Hasholzner, U
De Bruijn, H
Dobbler, D
Dombi, VH
Fink, D
Giai, M
Mcging, P
Harlozinska, A
Kainz, C
Markowska, J
Molina, R
Sturgeon, C
Bowman, A
Einarsson, R
Citation: A. Van Dalen et al., Serum levels of CA 125 and TPS during treatment of ovarian cancer, ANTICANC R, 20(6D), 2000, pp. 5107-5108
Authors:
Bar, JK
Harlozinska, A
Citation: Jk. Bar et A. Harlozinska, Morphological and phenotypic characterzation of a new established ovarian carcinoma cell line (OvBH-1), ANTICANC R, 20(5A), 2000, pp. 2975-2980
Authors:
Harlozinska, A
Bar, JK
Montenarh, M
Citation: A. Harlozinska et al., Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas, ANTICANC R, 20(2A), 2000, pp. 1049-1056
Authors:
van Dalen, A
Favier, J
Burges, A
Hasholzner, U
de Bruijn, HWA
Dobler-Girdziunaite, D
Dombi, VH
Fink, D
Giai, M
McGing, P
Harlozinska, A
Kainz, C
Markowska, J
Molina, R
Sturgeon, C
Bowman, A
Einarsson, R
Citation: A. Van Dalen et al., Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients, GYNECOL ONC, 79(3), 2000, pp. 444-450
Authors:
Van Dalen, A
Favier, J
Baumgartner, L
Hasholzner, U
De Bruijn, H
Dobbler, D
Dombi, VH
Fink, D
Giai, M
McGing, P
Harlozinska, A
Kainz, C
Markowska, J
Molina, R
Sturgeon, C
Einarsson, R
Citation: A. Van Dalen et al., Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients, ANTICANC R, 19(4A), 1999, pp. 2523-2526
Risultati:
1-8
|